Interleukin-4 and Tumour Necrosis Factor-alpha Produce Non Isotype Specific Partial Differentiation of Peripheral Blood B-Cells in Myeloma

References

• Barlogie B., Epstein J., Selvanayagam P., Alexanian R. Plasma cell myeloma. New biological insights and advances in therapy. Blood 1989; 73: 865–879
   PubMed Web of Science ®Google Scholar
• Mellstedt H., Hammarstrom S., Holn G. Monoclonal lymphocyte-population in human plasma cell myeloma. Clinical and experimental Immunology 1974; 17: 371–384
   PubMed Web of Science ®Google Scholar
• Pilarski L. M., Belch A. B. Circulating monoclonal B-cells expressing P glycoprotein may be a reservoir of multiple-drug resistant disease in multiple myeloma. Blood 1994; 83: 724–736
   PubMed Web of Science ®Google Scholar
• Bergsagel P. L., Masellis Smith A., Szczepek A., Mant M. J., Belch A. R., Pilarski L. M. In multiple myeloma, clonotypic B-lymphocytes are detectable among CD 19 peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 1995; 85: 436–447
   PubMed Web of Science ®Google Scholar
• Takishita M., Kosaka M., Goto T., Saito S. Cellular origin and extent of clonal involvement in multiple myeloma: genetic and phenotypic studies. British Journal of Haematology 1994; 87: 735–742
   PubMed Web of Science ®Google Scholar
• Bakkus M. H. C., Van Riet I., Van Camp B., Thielemans K. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but soma-tically mutated B-cell. British Journal of Haematology 1994; 87: 68–74
   PubMed Web of Science ®Google Scholar
• King M. A., Wells J. V. Paraproteinaemia: Use of idiotypic determinants as specific markers for tumour activity. Clinical and Experimental Immunology 1981; 45: 544
   PubMed Web of Science ®Google Scholar
• Kay N. E., Oken M. M., Bone N., Kyle R. A., Greipp P., Van Ness B., Leong T. Circulating CD19+ blood cell levels in myeloma, (letter). Blood 1996; 4000
   Web of Science ®Google Scholar
• McSweeney P. A., Wells D. A., Schuts K. E., Nash R. A., Bensinger W. I., Buckner C. D., Loken M. R. Tumor-specific aneuploidy not detected in CD 19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis. Blood 1996; 88: 622–632
   PubMed Web of Science ®Google Scholar
• Chen B. J., Epstein J. Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B-cells. Blood 1996; 87: 1972–1976
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F., Bergui L., Gregoretti M. G., Gaidano G., Gaboli M., Schena M., Zallone A. Z., Marchisio P. S. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991; 77: 2688–2693
   PubMed Web of Science ®Google Scholar
• Bergui L., Schena M., Gaidano G., Riva M., Caligaris-Cappio F. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. Journal of Experimental Medicine 1989; 170: 613–618
   PubMed Web of Science ®Google Scholar
• Tokumine Y., Nishimori Y., Shibayama H., et al. Failure of IL-3 plus IL-6 to induce the proliferation and differentiation of malignant plasma cell precursors from peripheral blood in multiple myeloma. Leukaemia 1993; 7: 333–335
   PubMed Web of Science ®Google Scholar
• Sawamura M., Murakami H., Tamura J., et al. Tumour necrosis factor-alpha and interleukin 4 promote the differentiation of myeloma cell precursors in multiple myeloma. British Journal of Haematology 1994; 88: 17–23
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X.-G., Lu Z.-Y., Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85: 863–872
   PubMed Web of Science ®Google Scholar
• Akashi K. The role of interleukin-4 in the negative regulation of leukemia cell growth (review). Leukemia Lymphoma 1993; 9: 205–209
   PubMed Web of Science ®Google Scholar
• Defrance T., Vanbervliet B., Aubry J.-P., Takebe Y., Arai N., Miyajima A., Yokota T., Lee F., Arai K., de Vries J. E., Banchereau J. B-cell growth-promoting activity of recombinant human interleukin 4. Journal of Immunology 1987; 139: 1135–1140
   PubMed Web of Science ®Google Scholar
• Llorente L., Mitjavila F., Crevon M.-C., Galanaud P. Dual effects of interleukin 4 on antigen-activated human B-cells: Induction of proliferation and inhibition of interleukin 2-dependent differentiation. European Journal of Immunology 1990; 20: 1887
   PubMed Web of Science ®Google Scholar
• Lundgren M., Persson U., Larsson P., Magnusson C., Smith C. I. E., Hammarstrom L., Severinson E. Interleukin 4 induces synthesis of IgE and IgG4 in human B-cells. European Journal of Immunology 1989; 19: 1311
   PubMed Web of Science ®Google Scholar
• Noelle R. J., Ledbetter J. A., Aruffo A. CD40 and its ligand, an essential ligand-receptor pair for thymus dependent B-cell activation. Immunology Today 1992; 13: 427
   PubMedGoogle Scholar
• Banchereau J., Bazan F., Blanchard D., Briere F., Galizzi J. P., Van Kooten C., Liu Y. J., Rousset F., Saeland S. The CD40 antigen and its ligand. Annual Review Immunology 1994; 52: 881–922
   Google Scholar
• Banchereau J., de Paoli P., Valle A., Garcia E., Rousset F. Long-term human B-cell lines dependent on interleukin-4 and antibody to CD40. Science 1991; 251: 70–72
   PubMed Web of Science ®Google Scholar
• Aversa G., Punnonen J., de Vries J. E. The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T-cell clones provides a costimulatory signal for human B-cell activation. Journal of Experimental Medicine 1993; 177: 1575
   PubMed Web of Science ®Google Scholar
• Hollenbaugh D., Grosmaire L. S., Kullas C. D., Chalupny N. J., Braesch-Andersen S., Noelle R. J., Stamenkovic I., Ledbetter J. A., Aruffo A. The human T-cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: Expression of a soluble form of gp39 with B-cell co-stimulatory activity. EMBO Journal 1992; 11: 4313
   PubMed Web of Science ®Google Scholar
• Smeland E. B., Blomholff H. K., Funderud S., Shalaby M. R., Espevik T. Interleukin 4 induces selective production of interleukin 6 from normal human B lymphocytes. Journal of Experimental Medicine 1989; 170: 1463
   PubMed Web of Science ®Google Scholar
• Paul W. E. Interleukin-4: a proteolytic immunoregulatory lymphokine. Blood 1991; 77: 1859–1870
   PubMed Web of Science ®Google Scholar
• Te Velde A. A., Klomp J. P. G., Yard B. A., de Vries J. E., Figdor C. G. Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4. Journal of Immunology 1988; 140: 1548
   PubMed Web of Science ®Google Scholar
• Hart P. H., Vitti G. F., Burgess D. R., Whitty G. A., Piccoli D. S., Hamilton J. A. Potential antiinflammatory effects of interleukin-4: Suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2. Proceedings of National Academy of Science USA 1989; 86: 3803
   PubMed Web of Science ®Google Scholar
• Tucci A., James H., Chicheportiche R., Bonnefoy J.-Y., Dayer J. M., Zubler R. H. Effects of eleven cytokines and of II-1 and tumor necrosis factor inhibitors in a human B-cell assay. Journal of Immunology 1992; 148: 2778
   PubMed Web of Science ®Google Scholar
• Gauchat J.-F., Aversa G., Gascan H., de Vries J. E. Modulation of IL-4 induced germline epsilon RNA synthesis in human B-cells by tumor necrosis factor-alpha, anti-CD40 monoclonal antibodies or transforming growth factor-beta correlates with levels of IgE production. International Immunology 1992; 4: 397–406
   PubMed Web of Science ®Google Scholar
• Carter A., Merchav S., Silvian-Draxler I., et al. The role of interleukin-1 and tumor necrosis factor-alpha in human multiple myeloma. British Journal of Haematology 1990; 74: 424–431
   PubMed Web of Science ®Google Scholar
• Lichenstein A., Berenson J., Norman D., Chang M. P., Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 1989; 74: 1266–1273
   PubMed Web of Science ®Google Scholar
• Hata H., Matsuzaki H., Takatsuki K. Autocrine growth by two cytokines, interleukin-6 and tumour necrosis factor alpha, in the myeloma cell line KHM-la. Acta Haematologica 1990; 83: 113–136
   PubMedGoogle Scholar
• Jensen G. S., Mant M. J., Belch A. J., Berensen J. R., Ruether B. A., Pilarski L. M. Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from meloma patients as late stage IB-cells. Blood 1991; 78: 711–719
   PubMed Web of Science ®Google Scholar
• Jacobson D. R., Zolla-Pazners. Immunosuppression and infection in multiple myeloma. Seminars in Oncology 1986; 8: 282
   Google Scholar
• Salmon S. E. Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Seminars in Hematology 1973; 10: 135–147
   PubMed Web of Science ®Google Scholar
• Broder S., Humphrey R., Durm M., Blackman M., Meade B., Goldman C., Strober W., Waldmann T. Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma. New England Journal of Medicine 1975; 293: 887–892
   PubMed Web of Science ®Google Scholar
• Knapp W., Baumgartner G. Monocyte-mediated suppression of human B-lymphocyte differentiation in vitro. Journal of Immunology 1978; 121: 1177–1182
   PubMed Web of Science ®Google Scholar
• Hoover R. G., Hickman S., Gebel H., Rebbe N., Lynch R. Expansion of Fc receptor bearing T-lymphocytes in patients with immunoglobulin G and immunoglobulin A myeloma. Journal of Clinical Investigation 1981; 67: 308–311
   PubMed Web of Science ®Google Scholar
• MacKenzie M. R., Paglieroni T. G., Warner N. L. Multiple myeloma: An immunologic profile. IV. The EA rosette-forming cell is a Leu-1 positive immunoregulatory B-cell. Journal of Immunology 1987; 139: 24–28
   PubMed Web of Science ®Google Scholar
• Tienhaara A., Pelliniemi T.-T. Peripheral blood B-lymphocytes in multiple myeloma. Acta Haematologica 1994; 91: 57–61
   PubMed Web of Science ®Google Scholar
• Pilarski L. M., Ruether B. A., Mant M. J. Abnormal function of B lymphocytes from peripheral blood of multiple myeloma patients. Lack of correlation between the number of cells potentially able to secrete immunoglobulin M and serum immunoglobulin M levels. Journal of Clinical Investigation 1985; 75: 2024–2029
   PubMed Web of Science ®Google Scholar
• Tsujimoto T., Lisukov I. A., Huang N., Mahmoud M. S., Kawano M. M. Plasma cells induce apoptosis of pre-B-cells by interacting with bone marrow stromal cells. Blood 1996; 87: 3375–3383
   PubMed Web of Science ®Google Scholar
• Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83–85
   PubMed Web of Science ®Google Scholar
• Kyrstsonis M.-C, Dedoussis G., Baxevanis C., Stamarelou M., Maniatis A. Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM). British Journal of Haematology 1996; 92: 420–422
   PubMed Web of Science ®Google Scholar
• Osterborg A., Steinitz M., Lewin N., et al. Establishment of idiotype bearing B-lymphocyte clones from a patient with monoclonal gammopathy. Blood 1991; 78: 2642–2649
   PubMed Web of Science ®Google Scholar
• King M. A., Nelson D. S. Tumor cell heterogeneity in multiple myeloma: antigenic, morphologic and functional studies of cells from blood and bone marrow. Blood 1989; 73: 1925–1935
   PubMed Web of Science ®Google Scholar
• Saily M., Koistinen P., Laine S., Soppi E., Savolainen E.-R. Production of immunolobulin isotypes by peripheral blood mononuclear cells in multiple myeloma. Acta Haematologica 1994; 92: 71–78
   PubMed Web of Science ®Google Scholar
• Taylor C. W., Grogan T. M., Salmon S. E. Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood 1990; 75: 1114–1118
   PubMed Web of Science ®Google Scholar
• Herrmann F., Andreeff M., Gruss H.-J., Brach M. A., Lubbert M., Mertelsmann R. Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression. Blood 1991; 78: 2070–2074
   PubMed Web of Science ®Google Scholar